Changes to the Code
S. 4106 · Rx ACCESS Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
Introduced · step 1 of 5
10 U.S.C. § 1074g Pharmacy benefits program
4 changes the bill asks for here, 4 carried out
- Carried out:
in subparagraph (A), by inserting
, and ending on October 1, 2026
afterBeginning on October 1, 2015
; and - Carried out:
by adding at the end the following new subparagraph:
(D) Beginning on October 1, 2026, an eligible covered beneficiary may elect to receive non-generic prescription maintenance medications through any means described in paragraph (2)(E)..
- Carried out:
by redesignating subsections (i) and (j) as subsections (j) and (k), respectively; and
- Carried out:
by inserting after subsection (h) the following new subsection:
(i) Pharmacy benefit manager reimbursement standards.— (1) The Secretary of Defense shall ensure that, as a condition of any contract entered into for the administration of the pharmacy benefits program, reimbursement to a retail pharmacy described in subsection (a)(2)(E)(ii) …
§ 1074g(a)Pharmacy Benefits.—(8)–(9)
Start of § 1074g to (a)(7) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (8) | (8) | (8) | ||
| In carrying out this subsection, the Secretary shall ensure that an eligible covered beneficiary may continue to receive coverage for any maintenance pharmaceutical that is not on the uniform formulary and that was prescribed for the beneficiary before October 5, 1999, and stabilized the medical condition of the beneficiary. | In carrying out this subsection, the Secretary shall ensure that an eligible covered beneficiary may continue to receive coverage for any maintenance pharmaceutical that is not on the uniform formulary and that was prescribed for the beneficiary before October 5, 1999, and stabilized the medical condition of the beneficiary. | |||
| (9) | (9) | (9) | ||
| (9)(A) | (A) | (A) | ||
| Beginning on October 1, 2015, the pharmacy benefits program shall require eligible covered beneficiaries generally to refill non-generic prescription maintenance medications through military treatment facility pharmacies or the national mail-order pharmacy program. | Beginning on October 1, 2015, [inserted: and ending on October 1, 2026, ]the pharmacy benefits program shall require eligible covered beneficiaries generally to refill non-generic prescription maintenance medications through military treatment facility pharmacies or the national mail-order pharmacy program. | |||
| (9)(B) | (B) | (B) | ||
| The Secretary shall determine the maintenance medications subject to the requirement under subparagraph (A). The Secretary shall ensure that— | The Secretary shall determine the maintenance medications subject to the requirement under subparagraph (A). The Secretary shall ensure that— | |||
| (9)(B)(i) | (i) | (i) | ||
| such medications are generally available to eligible covered beneficiaries through retail pharmacies only for an initial filling of a 30-day or less supply; and | such medications are generally available to eligible covered beneficiaries through retail pharmacies only for an initial filling of a 30-day or less supply; and |
§ 1074g(a)Pharmacy Benefits.—(9)–(10)
(a)(9)(B)(ii)–(C) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (9)(C)(i) | (i) | (i) | ||
| Medications that are for acute care needs. | Medications that are for acute care needs. | |||
| (9)(C)(ii) | (ii) | (ii) | ||
| Such other medications as the Secretary determines appropriate. | Such other medications as the Secretary determines appropriate. | |||
| (9)(D) | (D) [inserted: ] | |||
| [inserted: Beginning on October 1, 2026, an eligible covered beneficiary may elect to receive non-generic prescription maintenance medications through any means described in paragraph (2)(E).] | ||||
| (10) | (10) | (10) | ||
| Notwithstanding paragraphs (2), (5), and (6), in order to encourage the use by covered beneficiaries of pharmaceutical agents that provide the best clinical effectiveness to covered beneficiaries and the Department of Defense (as determined by the Secretary, including considerations of better care, healthier people, and smarter spending), the Secretary may, upon the recommendation of the Pharmacy and Therapeutics Committee established under subsection (b) and review by the Uniform Formulary Beneficiary Advisory Panel established under subsection (c)— | Notwithstanding paragraphs (2), (5), and (6), in order to encourage the use by covered beneficiaries of pharmaceutical agents that provide the best clinical effectiveness to covered beneficiaries and the Department of Defense (as determined by the Secretary, including considerations of better care, healthier people, and smarter spending), the Secretary may, upon the recommendation of the Pharmacy and Therapeutics Committee established under subsection (b) and review by the Uniform Formulary Beneficiary Advisory Panel established under subsection (c)— | |||
| (10)(A) | (A) | (A) | ||
| exclude from the pharmacy benefits program any pharmaceutical agent that the Secretary determines provides very little or no clinical effectiveness to covered beneficiaries and the Department under the program; and | exclude from the pharmacy benefits program any pharmaceutical agent that the Secretary determines provides very little or no clinical effectiveness to covered beneficiaries and the Department under the program; and | |||
§ 1074g(g)–(k)
(a)(10)(B)–(g)(4)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (g)(5) | (5) | (5) | ||
| For purposes of this subsection, any reference to a program operated by a State includes any program operated by a county, municipality, or other subdivision within that State. | For purposes of this subsection, any reference to a program operated by a State includes any program operated by a county, municipality, or other subdivision within that State. | |||
| (h) | (h) Labeling.— | (h) Labeling.— | ||
| The Secretary of Defense shall ensure that drugs made available through the facilities of the armed forces under the jurisdiction of the Secretary include labels and other labeling that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). | The Secretary of Defense shall ensure that drugs made available through the facilities of the armed forces under the jurisdiction of the Secretary include labels and other labeling that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). | |||
| (i) | (i) [inserted: Pharmacy benefit manager reimbursement standards.—] | |||
| (i)(1) | (1) [inserted: ] | |||
| [inserted: The Secretary of Defense shall ensure that, as a condition of any contract entered into for the administration of the pharmacy benefits program, reimbursement to a retail pharmacy described in subsection (a)(2)(E)(ii) for a pharmaceutical agent provided under such program shall be an amount that is equal to not less than the sum of—] | ||||
| (i)(1)(A) | (A) [inserted: ] | |||
| [inserted: either—] | ||||
| (i)(1)(A)(i) | (i) [inserted: ] | |||
| [inserted: the actual cost to the pharmacy of acquiring such pharmaceutical agent from a wholesaler, or] | ||||
| (i)(1)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: in the case of a pharmaceutical agent included on the national average drug acquisition cost index published by the Administrator of the Centers for Medicare & Medicaid Services, a proxy amount calculated at a rate that is not lower than the national average acquisition cost for such pharmaceutical agent, as identified on such cost index as of the date of the adjudication of the claim for such reimbursement, and] | ||||
| (i)(1)(B) | (B) [inserted: ] | |||
| [inserted: a professional dispensing fee that is equal to the professional dispensing fee paid by the State in which the pharmacy is located under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) for dispensing a prescription drug.] | ||||
| (i)(2) | (2) [inserted: ] | |||
| [inserted: The contractor administering the pharmacy benefits program may not impose any fees on a retail pharmacy described in subsection (a)(2)(E)(ii), including point-of-sale fees, retroactive fees, or other indirect or hidden fees.] | ||||
| (i)(3) | (3) [inserted: ] | |||
| (i)(3)(A) | (A) [inserted: ] | |||
| [inserted: Not less frequently than annually, the Comptroller General of the United States shall—] | ||||
| (i)(3)(A)(i) | (i) [inserted: ] | |||
| [inserted: conduct an audit of—] | ||||
| (i)(3)(A)(i)(I) | (I) [inserted: ] | |||
| [inserted: data reported by the contractor responsible for the administration of the pharmacy benefits program relating to the rates of reimbursement under paragraph (1) and any price concessions; and] | ||||
| (i)(3)(A)(i)(II) | (II) [inserted: ] | |||
| [inserted: the adequacy of the retail pharmacy network under the TRICARE program and access by eligible covered beneficiaries to such network, including with respect to continuity of care, geographic accessibility (taking into account factors in addition to travel time to and from a pharmacy, with special consideration for rural and underserved areas), and the extent to which elections by such beneficiaries under subsection (a)(9) reflect personal preference; and] | ||||
| (i)(3)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: submit the results of such audit to the Committee on Armed Services of the Senate and the Committee on Armed Services of the House of Representatives.] | ||||
| (i)(3)(B) | (B) [inserted: ] | |||
| [inserted: The Secretary shall ensure that, as a condition of any contract entered into for the administration of the pharmacy benefits program, the contractor provides the Comptroller General information required to conduct the audit under subparagraph (A).] | ||||
| (j) | [inserted: (j)] Definitions.— | |||
| In this section: | In this section: | |||
| (j)(1) | (1) | (1) | ||
| The term “eligible covered beneficiary” means a covered beneficiary for whom eligibility to receive pharmacy benefits through the means described in subsection (a)(2)(E) is established under this chapter or another provision of law. | The term “eligible covered beneficiary” means a covered beneficiary for whom eligibility to receive pharmacy benefits through the means described in subsection (a)(2)(E) is established under this chapter or another provision of law. | |||
| (j)(2) | (2) | (2) | ||
| The term “pharmaceutical agent” means drugs, biological products, and medical devices under the regulatory authority of the Food and Drug Administration. | The term “pharmaceutical agent” means drugs, biological products, and medical devices under the regulatory authority of the Food and Drug Administration. | |||
| (j)(3) | (3) | (3) | ||
| The term “over-the-counter drug” means a drug that is not subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | The term “over-the-counter drug” means a drug that is not subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | |||
| (j)(4) | (4) | (4) | ||
| The term “prescription drug” means a drug that is subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | The term “prescription drug” means a drug that is subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | |||
| (k) | [inserted: (k)] Regulations.— | |||
| The Secretary of Defense shall, after consultation with the other administering Secretaries, prescribe regulations to carry out this section. | The Secretary of Defense shall, after consultation with the other administering Secretaries, prescribe regulations to carry out this section. | |||